WOBURN, Mass. — We are pleased to announce that Aphios Pharma LLC will host a live webinar followed by Q&A on the science and technology of cannabis as a medicine.
This webinar will cover the science and technology of cannabis and cannabinoids as a medicine for several chronic diseases. On the science side, we will cover research and use of cannabis for anxiety and observational studies at the MIND Institute, Harvard Medical School. We will also touch on the research and use of cannabis for pain, opioid use disorder and multiple sclerosis. On the technology side, we will cover the manufacturing of pharmaceutical-grade cannabinoids from Cannabis sativa (marijuana) following current Good Manufacturing Practices (cGMP) of the US FDA. We will also cover the nanoencapsulation of these cannabinoids to improve their stability and sustain their release in the body to improve both safety and efficacy.
Join Aphios Pharma Founder and CEO, Dr. Trevor P. Castor, along with guests Dr. Staci A. Gruber, Associate Professor, Harvard Medical School, and Dr. Judith L. Palmer-Castor, Director, Clinical and Regulatory Affairs on June 23, 2022, from 1pm to 1:45pm EST for a discussion on the science of medical cannabis and the drug-delivery nanotechnologies that make cannabis more medically effective.
To learn more and register for the event, visit:
https://www.eventbrite.com/e/aphios-pharma-webinar-tickets-354629254647
About Aphios Pharma LLC:
Aphios Pharma is dedicated to the delivery, development and commercialization of cannabis-based drugs for CNS and other debilitating disorders. We are developing FDA-approved, cannabis-based drugs for treating highly unmet central and peripheral nervous system disorders such as opioid addiction and chemotherapy induced peripheral neuropathic pain that are only acutely addressed by medical marijuana. Aphios Pharma is utilizing patented and proprietary manufacturing technologies for producing pharmaceutical-grade cannabinoids, and patented and proprietary drug delivery nanotechnologies to improve the oral bioavailability of disease-specific cannabinoids and control their release for the treatment of chronic diseases. We are thus converting natural drugs that are anecdotally used to treat acute conditions into well-defined and characterized drugs for chronic conditions.
- Advocates, parents ‘beg’ Nebraskans to seek out and sign petition to legalize medical cannabis
Advocates for legalizing medical marijuana switched Wednesday from urging Nebraskans to sign their petition to begging them as a July 7 deadline looms to submit signatures to qualify for the ballot in November. - Iowans launch cannabis reform campaign aimed at showing public support
Robert “Lewy” Lewis of Windsor Heights has been in pain since 1974, when he had spinal surgery at the age of 21. To repair a blockage in his spine, surgeons removed eight inches of his vertebrae and then sewed them back on, using about 300 steel stitches. - Big Apple Cannabis: CWCB Returns to New York City for Eighth Year
“No one seems to have gotten it right.” Mayor Eric Adams told a Friday afternoon crowd, of legal cannabis in America. “This is our chance to get it right.” New York City’s mayor addressed attendees of the 2022 Cannabis World Congress & Business Expo (CWCBExpo) on the second day of the three-day event. Adams stressed the social equity focus of New York’s cannabis program. - Nebraska medical cannabis backers file legal challenge to petition process
Supporters of medical marijuana in Nebraska have launched a legal challenge to the state’s requirement that 5% of registered voters in at least 38 counties sign a petition to get the measure before voters on the ballot. - N.J. lawmakers seek to curb cannabis use
As New Jersey nears the end of its first month of legal recreational marijuana sales, lawmakers have introduced a series of bills aimed at restricting what types of workers can use cannabis off the job. - Missouri House votes to require disclosure of medical cannabis ownership records
The Missouri House voted overwhelmingly Tuesday to require state regulators to disclose ownership information for businesses granted medical marijuana licenses that the state has withheld from public view. - Nebraska medical cannabis group calls for ‘grassroots’ effort after losing donor
Unable to raise $1 million to replace funds from a major donor who died, Nebraskans for Medical Marijuana issued a plea Friday for supporters of the cause to take up petitions and gather signatures. - Lawmaker says GOP resistance may doom Missouri cannabis legalization
A Republican lawmaker pushing legislation to legalize recreational marijuana in Missouri says his bill is in jeopardy because of stall tactics by his GOP colleagues and the insistence of the House floor leader that it include license caps. - SD cannabis legalization campaign to submit signatures for November
Today, South Dakotans for Better Marijuana Laws, the political group that led the 2020 campaign to legalize cannabis in South Dakota, submitted petitions to place an adult-use cannabis legalization initiated measure on the November 2022 ballot. - NH senate votes down legal cannabis bills, ending chances for 2022
The New Hampshire Senate voted down two bills to legalize cannabis Thursday, likely heading off the last opportunities for legalization in the Granite State this year.